Accreditations and Designations
- National Cancer Institute (NCI)
- Joint Commission
- National Comprehensive Cancer Network (NCCN)
- Michigan Cancer Consortium (MCC)
- Commission on Cancer (CoC) of the American College of Surgeons
- The Quality Oncology Practice Initiative (QOPI®)
- Blue Distinction Center for Complex and Rare Cancers®
- Big Ten Cancer Research Consortium
National Cancer Institute
The National Cancer Institute has designated the University of Michigan Rogel Cancer Center a comprehensive cancer center. As an NCI-designated site, the cancer center receives a Support Grant awarded through a rigorous peer-review process that evaluates the scientific merit of an institution's programming. This means we meet strict guidelines and excel in:
- extensive, interactive and innovative clinical, laboratory and population research
- testing of new therapies in partnership with the NCI
- provision of patient education, community service and outreach
- training for health professionals
Learn more about the NCI cancer centers program.
As part of Michigan Medicine, the cancer center has earned accreditation from the Joint Commission. The Joint Commission, a voluntary accreditation system, is recognized as a world leader in setting the highest standards for health care quality.
To qualify for accreditation, Michigan Medicine is evaluated by specially trained health care experts who assess how well the staff:
- provides a safe environment for care
- educates patients about the risks and options for diagnosis and treatment
- protects patient rights, including privacy rights
- evaluates a patient's condition before, during and after diagnosis and treatment
- protects patients from infection
- plans for emergency situations
Joint Commission accreditation indicates the Rogel Cancer Center's commitment to providing the safest advanced care available.
Learn more about the Joint Commission.
National Comprehensive Cancer Network
The Rogle Cancer Center is one of 27 premier centers participating in the National Comprehensive Cancer Network. The NCCN is dedicated to improving the quality and effectiveness of care provided to patients with cancer. NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
Easy-to-understand versions of the guidelines are available to help patients and their families with making well-informed decisions about care. Treatment guidelines are available for a wide range of cancers as well as supportive care issues, such as cancer pain and nausea. Access the NCCN guidelines.
Michigan Cancer Consortium
The cancer center is a member of the Michigan Cancer Consortium. This statewide network of nearly 90 Michigan organizations is an ambitious public-private partnership. Together, we work to improve cancer outcomes for Michigan patients and to reduce the social, personal and economic burden cancer imposes on families, with an ultimate goal of improving cancer outcomes for Michigan residents.
The MCC has defined a set of public health priorities to help prevent cancer and improve standards of care. Priorities range from improving smoking-cessation rates to standardizing language among care providers to ensure appropriate care.
Since the cancer center's founding principles are rooted in the importance of collaboration, the center is proud to be working in partnership with other MCC members to reduce the devastating impact of cancer on Michigan citizens.
Learn more about the Michigan Cancer Consortium.
Commission on Cancer (CoC) of the American College of Surgeons
The CoC is a consortium of professional organizations dedicated to improving survival and quality of life for cancer patients through standard-setting, prevention, research, education, and the monitoring of comprehensive quality care.
The quality standards established by the CoC for cancer programs provide for:
- comprehensive care including a complete range of state-of-the-art services and equipment
- a multidisciplinary team approach to coordinate the best available treatment options
- information about ongoing cancer clinical trials and new treatment options
- access to prevention and early detection programs, cancer education and support services
- a cancer registry that offers lifelong patient follow-up
- ongoing monitoring and improvements in cancer care
- quality care, close to home
Learn more about the Commission on Cancer.
The Quality Oncology Practice Initiative (QOPI®)
The Cancer Center is recognized by the QOPI® Certification Program, an affiliate of the American Society of Clinical Oncology and its Quality Oncology Practice Initiative. The QOPI® Certification Program provides a three-year certification for outpatient hematology-oncology practices that meet standards for quality cancer care.
Learn more about QOPI®.
Blue Distinction Center for Complex and Rare Cancers®
The national Blue Cross and Blue Shield Association has designated the cancer center as a Blue Distinction Center. This means we meet strict requirements for delivering quality health care in specific specialties for adults, including comprehensive inpatient cancer care programs, delivered by multidisciplinary teams with subspecialty training and distinguished clinical expertise in treating complex and rare subtypes of cancer. Selection criteria used in designating Blue Distinction Centers for Complex and Rare Cancers were developed in collaboration with expert doctors and medical organizations, including the National Comprehensive Cancer Network.
The Rogel Cancer Center programs that have received this distinction are:
- Acute Leukemia - Inpatient, Non-Surgical
- Bone - Primary
- Brain - Primary
- Head and Neck
- Liver - Primary
- Ocular Melanoma
- Soft Tissue Sarcomas
- Thyroid - Medullary and/or Anaplastic
Big Ten Cancer Research Consortium
The Big Ten cancer centers have united to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team-research culture to drive science rapidly from ideas to treatment-changing paradigms. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.
Learn more at www.bigtencrc.org .